ProtoKinetix Announces Share Issuance and Closing of West Vancouver Office
07 March 2015 - 1:31PM
Business Wire
ProtoKinetix, Incorporated (OTC:PKTX) (www.protokinetix.com)
(the “Company” or “ProtoKinetix”) announces that it
has entered into an agreement with Clarence E. Smith, the Company’s
President and CEO, pursuant to which Mr. Smith has agreed to
purchase 15,000,000 shares of common stock of the Company at a
price of $0.025 per share, representing aggregate total proceeds of
$375,000, a portion of which had been advanced by Mr. Smith
previously to the Company to pay Company expenses.
As of March 15, 2015, the Company will close its office in West
Vancouver, British Columbia and transfer all operations to its West
Virginia office. Any public relations questions may be directed to
Blair Henderson at 604-356-3816. For any investor relations
questions, please contact the Company at 304-299-5070.
About ProtoKinetix
ProtoKinetix is a molecular biotechnology company that has
developed and patented a family of hyper stable, potent
glycopeptides (AAGP™) that dramatically enhance the therapeutic
results and reduce the cost of stem cell medicine. Due to the
anti-inflammatory effect of AAGP™ molecules, the Company is
currently targeting the direct treatment of diseases that have a
major inflammatory component.
ON BEHALF OF THE BOARD OF DIRECTORSPROTOKINETIX,
INCORPORATED
Clarence E. SmithPresident and Chief Executive Officer
Cautionary Statement Regarding Forward-Looking
Information
Except for statements of historical fact, this news release
contains certain “forward-looking information” within the meaning
of applicable securities law, including statements regarding the
potential treatments for which the Company's AAGPTM may be applied.
Forward-looking information is frequently characterized by words
such as “plan”, “expect”, “project”, “intend”, “believe”,
“anticipate”, “estimate” and other similar words, or statements
that certain events or conditions “may” or “will” occur.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those anticipated in the forward-looking statements. The Company
undertakes no obligation to update forward-looking information if
circumstances or management’s estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. More detailed
information about potential factors that could affect financial
results is included in the documents filed by the Company from time
to time with the United States Securities Commission and with
securities regulatory authorities in Canadian on SEDAR.
The Private Securities Litigation Reform Act of 1995 provides a
“safe harbor” for forward-looking statements. Some information
included in this press release contains statements that are
forward-looking. Such forward-looking information involves
significant risks and uncertainties that could affect anticipated
results in the future and, accordingly, these results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of the Company. For a description of
additional risks and uncertainties, please refer to the Company’s
filings with the Securities and Exchange Commission.
ProtoKinetix, IncorporatedClarence E. Smith,
304-299-5070President & Chief Executive
Officercsmith@protokinetix.com
Protokinetix (QB) (USOTC:PKTX)
Historical Stock Chart
From Apr 2024 to May 2024
Protokinetix (QB) (USOTC:PKTX)
Historical Stock Chart
From May 2023 to May 2024